Immunotherapy for hormone receptor-positive HER2-negative breast cancer

被引：0
|
作者：
Cardoso, Fatima [1 ]
Hirshfield, Kim M. [2 ]
Kraynyak, Kimberly A. [2 ]
Tryfonidis, Konstantinos [2 ]
Bardia, Aditya [3 ]
机构：
[1] Champalimaud Fdn, Champalimaud Clin Ctr, Breast Unit, Lisbon, Portugal
[2] Merck & Co Inc, Rahway, NJ USA
[3] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Dept Med, Div Hematol Oncol, Los Angeles, CA USA
来源：
NPJ BREAST CANCER | 2024年 / 10卷 / 01期
关键词：
PEMBROLIZUMAB PLUS CHEMOTHERAPY; TUMOR-INFILTRATING LYMPHOCYTES; ADJUVANT ENDOCRINE THERAPY; OPEN-LABEL; HIGH-RISK; NEOADJUVANT CHEMOTHERAPY; LOCALLY RECURRENT; NIVOLUMAB NIVO; TRIAL; PALBOCICLIB;
D O I：
10.1038/s41523-024-00704-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Additional therapies are needed to improve outcomes in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer. Research on the potential role of immunotherapy, particularly programmed cell death protein 1/programmed cell death ligand 1 inhibitors, is rapidly expanding in both the early and metastatic settings with some preliminary evidence suggesting benefit when used as part of combination therapy. Several ongoing phase 3 studies should help define their future role in treating these patients.
引用
收藏
页数：15
相关论文
共 50 条
  • [21] Treatment differences by race and age in metastatic hormone receptor-positive/HER2-negative breast cancer
    Abdou, Yara
    Ivory, Joannie
    Deal, Allison
    Wardell, Ally
    Wheless, Amy
    Dees, Claire
    Carey, Lisa
    CANCER RESEARCH, 2024, 84 (09)
  • [22] Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases
    Minetta C. Liu
    Javier Cortés
    Joyce O’Shaughnessy
    Cancer and Metastasis Reviews, 2016, 35 : 323 - 332
  • [23] Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer
    Burstein, Harold J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (12): : 1176 - 1177
  • [24] Patterns of chemotherapy receipt among patients with hormone receptor-positive, HER2-negative breast cancer
    Olsson, Linnea T.
    Hamilton, Alina M.
    Van Alsten, Sarah C.
    Lund, Jennifer L.
    Sturmer, Til
    Nichols, Hazel B.
    Reeder-Hayes, Katherine E.
    Troester, Melissa A.
    BREAST CANCER RESEARCH AND TREATMENT, 2024, 204 (01) : 107 - 116
  • [25] Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases
    Liu, Minetta C.
    Cortes, Javier
    O'Shaughnessy, Joyce
    CANCER AND METASTASIS REVIEWS, 2016, 35 (02) : 323 - 332
  • [26] Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer
    Burstein, Harold J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (26): : 2557 - 2570
  • [27] Neoadjuvant Therapy for weak receptor-positive/HER2-negative Breast Cancer
    Judith Lorenz, Kuenzell
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (11) : 1124 - 1124
  • [28] Prognostic Value of EndoPredict in Women with Hormone Receptor-Positive, HER2-Negative Invasive Lobular Breast Cancer
    Sestak, Ivana
    Filipits, Martin
    Buus, Richard
    Rudas, Margaretha
    Balic, Marija
    Knauer, Michael
    Kronenwett, Ralf
    Fitzal, Florian
    Cuzick, Jack
    Gnant, Michael
    Greil, Richard
    Dowsett, Mitch
    Dubsky, Peter
    CLINICAL CANCER RESEARCH, 2020, 26 (17) : 4682 - 4687
  • [29] Efficacy of palbociclib after everolimus in hormone receptor-positive, HER2-negative advanced breast cancer.
    Kovac, Anja
    Kuhar, Cvetka Grasic
    Ovcaricek, Tanja
    Matos, Erika
    Mencinger, Marina
    Borstnar, Simona
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [30] Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer
    Falato, Claudette
    Schettini, Francesco
    Pascual, Tomas
    Braso-Maristany, Fara
    Prat, Aleix
    CANCER TREATMENT REVIEWS, 2023, 112
12345